Lidds AB (ST:LIDDS) — Market Cap & Net Worth
Market Cap & Net Worth: Lidds AB (LIDDS)
Lidds AB (ST:LIDDS) has a market capitalization of $361.27K (Skr3.36 Million) as of May 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30651 globally and #727 in its home market, demonstrating a 17.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lidds AB's stock price Skr0.02 by its total outstanding shares 136463326 (136.46 Million). Analyse Lidds AB cash conversion from operations to see how efficiently the company converts income to cash.
Lidds AB Market Cap History: 2015 to 2026
Lidds AB's market capitalization history from 2015 to 2026. Data shows change from $108.78 Million to $361.27K (-42.71% CAGR).
Index Memberships
Lidds AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.00% | #250 of 281 |
Weight: Lidds AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lidds AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lidds AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
46.58x
Lidds AB's market cap is 46.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $200.87 Million | $1.03 Million | -$6.67 Million | 195.30x | N/A |
| 2018 | $204.24 Million | $7.75 Million | -$3.75 Million | 26.34x | N/A |
| 2020 | $201.33 Million | $345.00K | -$32.33 Million | 583.57x | N/A |
| 2021 | $130.35 Million | $3.55 Million | -$37.27 Million | 36.68x | N/A |
| 2022 | $23.15 Million | $1.89 Million | -$36.86 Million | 12.26x | N/A |
| 2023 | $1.59 Million | $-110.00K | -$40.21 Million | -14.42x | N/A |
| 2024 | $1.49 Million | $32.00K | -$5.94 Million | 46.58x | N/A |
Competitor Companies of LIDDS by Market Capitalization
Companies near Lidds AB in the global market cap rankings as of May 3, 2026.
Key companies related to Lidds AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Lidds AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Lidds AB's market cap moved from $108.78 Million to $ 361.27K, with a yearly change of -42.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr361.27K | -44.09% |
| 2025 | Skr646.17K | -56.65% |
| 2024 | Skr1.49 Million | -6.02% |
| 2023 | Skr1.59 Million | -93.15% |
| 2022 | Skr23.15 Million | -82.24% |
| 2021 | Skr130.35 Million | -35.25% |
| 2020 | Skr201.33 Million | -4.88% |
| 2019 | Skr211.65 Million | +3.63% |
| 2018 | Skr204.24 Million | +1.68% |
| 2017 | Skr200.87 Million | +140.32% |
| 2016 | Skr83.58 Million | -23.16% |
| 2015 | Skr108.78 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Lidds AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $361.27K USD |
| MoneyControl | $361.27K USD |
| MarketWatch | $361.27K USD |
| marketcap.company | $361.27K USD |
| Reuters | $361.27K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more